CYP19A1 and breast carcinoma: Clarification of the molecular mechanisms of the effect of haplotype CYP19 genetic polymorphism, such as mRNA stabilization, transcription enhancement, or posttranslational upregulation of aromatase expression [37], in this group of breast cancer patients is needed.